Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LFG316 in paroxysmal nocturnal hemoglobinuria (open-label proof-of-concept)
2014-005338-74Phase 2Completed
- Sponsor
- Novartis
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tesidolumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Novartis. Primary endpoint: Reduction in serum LDH levels within the first 4 weeks of treatment. Started Apr 2015; status: completed.
02
Drugs
tesidolumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2014-005338-74.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005338-74.